Steven Shak Sells 50,000 Shares of Genomic Health, Inc. (NASDAQ:GHDX) Stock

Genomic Health, Inc. (NASDAQ:GHDX) insider Steven Shak sold 50,000 shares of Genomic Health stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $71.83, for a total transaction of $3,591,500.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Steven Shak also recently made the following trade(s):

  • On Friday, August 2nd, Steven Shak sold 50,000 shares of Genomic Health stock. The stock was sold at an average price of $72.65, for a total transaction of $3,632,500.00.
  • On Friday, June 14th, Steven Shak sold 35,550 shares of Genomic Health stock. The stock was sold at an average price of $51.86, for a total transaction of $1,843,623.00.
  • On Wednesday, June 12th, Steven Shak sold 50,000 shares of Genomic Health stock. The stock was sold at an average price of $51.38, for a total transaction of $2,569,000.00.

Shares of Genomic Health stock traded up $0.01 during trading on Wednesday, hitting $73.17. The company’s stock had a trading volume of 907,279 shares, compared to its average volume of 582,549. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.74 and a quick ratio of 5.67. The business’s fifty day moving average price is $60.53. The firm has a market capitalization of $2.72 billion, a P/E ratio of 69.69 and a beta of 1.06. Genomic Health, Inc. has a 52 week low of $50.77 and a 52 week high of $92.18.

Genomic Health (NASDAQ:GHDX) last issued its quarterly earnings results on Monday, July 29th. The medical research company reported $0.42 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.35 by $0.07. The company had revenue of $114.14 million during the quarter, compared to analyst estimates of $110.78 million. Genomic Health had a net margin of 11.69% and a return on equity of 19.51%. Genomic Health’s quarterly revenue was up 19.4% compared to the same quarter last year. During the same period last year, the business earned $0.23 EPS. As a group, equities research analysts anticipate that Genomic Health, Inc. will post 1.5 EPS for the current fiscal year.

Several analysts have recently issued reports on the stock. BidaskClub raised shares of Genomic Health from a “buy” rating to a “strong-buy” rating in a research report on Tuesday. Needham & Company LLC lowered shares of Genomic Health from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 30th. ValuEngine upgraded shares of Genomic Health from a “hold” rating to a “buy” rating in a report on Saturday, July 27th. Canaccord Genuity lowered shares of Genomic Health from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $77.00 to $72.00 in a report on Tuesday, July 30th. Finally, Piper Jaffray Companies lowered shares of Genomic Health from an “overweight” rating to a “neutral” rating in a report on Monday, July 29th. Nine analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $69.86.

Institutional investors have recently modified their holdings of the stock. Acadian Asset Management LLC grew its position in Genomic Health by 20.5% during the 1st quarter. Acadian Asset Management LLC now owns 893,114 shares of the medical research company’s stock valued at $62,561,000 after purchasing an additional 151,846 shares during the last quarter. FMR LLC boosted its stake in shares of Genomic Health by 83.8% during the fourth quarter. FMR LLC now owns 550,627 shares of the medical research company’s stock valued at $35,466,000 after purchasing an additional 251,085 shares during the period. OppenheimerFunds Inc. boosted its stake in shares of Genomic Health by 30.0% during the first quarter. OppenheimerFunds Inc. now owns 469,560 shares of the medical research company’s stock valued at $32,893,000 after purchasing an additional 108,337 shares during the period. Clearbridge Investments LLC boosted its stake in shares of Genomic Health by 21.6% during the first quarter. Clearbridge Investments LLC now owns 340,847 shares of the medical research company’s stock valued at $23,876,000 after purchasing an additional 60,432 shares during the period. Finally, Norges Bank purchased a new stake in shares of Genomic Health during the fourth quarter valued at $20,975,000. Institutional investors own 95.15% of the company’s stock.

Genomic Health Company Profile

Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.

Featured Story: Using other technical indicators with support levels

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.